ClinicalTrials.gg
TerminatedNCT06639087AURORAUpdated Sep 24, 2025

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

A Phase 1 interventional study of AZD5462 and Dapagliflozin in Renal Impairment and Heart Failure, sponsored by AstraZeneca. Terminated at 1 site in Bulgaria. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
28th of 29
8 · median 24
Started
2024
with 5 others
Phase 1
26 of 29
none open now
Registered
23rd of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 28th largest by enrollment, is one of 6 that started in 2024, is one of 26 in phase 1, and was the 23rd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment.

Read the detailed description

This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate the safety, pharmacodynamics, and pharmacokinetics of AZD5462 on top of dapagliflozin in participants with heart failure and renal impairment.

The study will include 5 periods and approximately 9 study site visits:

  • Screening Period of up to 4 weeks (at least one study visit)
  • Run-in Period of up to 4 weeks (one study visit)
  • Inpatient Treatment Period of 4 days (one study visit)
  • Outpatient Treatment Period of up to 4 weeks (three study visits)
  • Follow-up Period of up to 4 weeks (three study visits)
03

Conditions studied

  • Renal Impairment
  • Heart Failure

Keywords

  • Relaxin family peptide receptor 1 agonist
  • Estimated glomerular filtration rate
  • Heart failure
  • Renal impairment
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a pre-existing diagnosis of heart failure (HF).
  • Participants must have a (LVEF) of ≤ 40% based on echocardiography taken within the last 9 months.
  • Participants must have an estimated (eGFR) of 30 to 60 milliliters per minute per 1.73 meters squared (mL/min/1.73 m2) (inclusive) at Screening as assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 (creatinine) equation.
  • Participants must be on stable HF standard of care (SoC) medication for at least 4 weeks prior to Screening. If the participant is currently taking diuretics, then diuretics must also be stable for at least one week prior to Screening.
  • Participants must be on stable Sodium-glucose co-transporter-2 inhibitors (SGLT2) inhibitor treatment for at least 12 weeks prior to Screening.
  • Minimum of 18 kilograms per meter squared (kg/m2) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Historical or current evidence of a disease or disorder.
  • Participants with a known to AZD5462 or dapagliflozin, or to any of the of these drug products.
  • Congenital long syndrome or history of QT prolongation associated with other medications that required discontinuation of that medication.
  • Cardiac ventricular arrhythmia that requires treatment. However, participants with atrial fibrillation or flutter and controlled ventricular rate (eg, resting heart rate \< 110 beats per minute) are permitted. Participants with cardiac ventricular arrhythmia that are treated with antiarrhythmic agents (eg, amiodarone) and are stable are permitted.
  • History of or anticipated heart transplant.
  • Any planned highly invasive cardiovascular procedure (eg, coronary revascularisation, valve repair/replacement, aortic aneurysm surgery).
  • Any evidence of clinically important disease or disorder which in the Investigator's opinion makes it undesirable for the participant to participate in the study.
  • Positive antibody, virus surface antigen, or hepatitis B virus core antibody at Screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    AZD5462 + dapagliflozin

    Participants will receive AZD5462 on top of dapagliflozin once daily.

    Drug: AZD5462 · Drug: Dapagliflozin

  • Placebo comparator
    Placebo + dapagliflozin

    Participants will receive placebo on top of dapagliflozin once daily.

    Drug: Dapagliflozin · Other: Placebo

Interventions

  • Participants will receive AZD5462 on top of dapagliflozin once daily.

  • Participants will receive dapagliflozin once daily with AZD5462 or placebo.

  • OtherPlacebo

    Participants will receive placebo on top of dapagliflozin once daily.

06

What researchers measure

Primary outcomes

  1. Change in sodium excretion

    To evaluate the effect of AZD5462 on top of dapagliflozin in participants with heart failure (HF) and renal impairment.

    Time frame: From Baseline to Day 1

Secondary outcomes

  1. Change in urine albumin-creatinine ratio (uACR)

    To evaluate the effect of AZD5462 on top of dapagliflozin in participants with HF and renal impairment.

    Time frame: From Baseline to Day 1 and 29

  2. Change in haematocrit

    To evaluate the effect of AZD5462 on top of dapagliflozin in participants with HF and renal impairment.

    Time frame: From Baseline to Day 29

  3. Number of adverse events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the effect of AZD5462 on top of dapagliflozin in participants with HF and renal impairment.

    Time frame: From Baseline to Day 57

07

Study locations

1 site
  • Research Site
    Sofia, 1612, Bulgaria
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in May 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Oct 15, 2024
StartActual
Sep 27, 2024
Primary completionActual
May 29, 2025
CompletionActual
May 29, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639087
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Sep 27, 2024
Primary completion
May 29, 2025
Completion
May 29, 2025
Last update
Sep 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pexerelgon

Start the discussion